Jha Smita, Bhattacharyya Timothy
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center Drive, Bldg 10-CRC, Room 4-1341, Bethesda, MD, USA.
Arch Osteoporos. 2016 Dec;11(1):28. doi: 10.1007/s11657-016-0283-2. Epub 2016 Aug 30.
There is a strong impetus to prevent and treat osteoporosis to prevent fractures. $990 million dollars was spent on anti-osteoporosis drugs in 2013. As we shift our focus on primary prevention of fractures, providers are encouraged to find the most cost-effective anti-osteoporosis therapy for patients.
Osteoporosis is a major global problem with osteoporotic fractures posing a potentially avoidable burden on healthcare resources. We studied the utilization and cost of anti-osteoporotic therapy using the 2013 Medicare Part D data.
Descriptive data were produced from Microsoft Excel and SPSS regarding the anti-osteoporotic drugs of interest.
In total, Medicare and its beneficiaries spent approximately $990 million on anti-osteoporotic therapy in 2013. Despite this cost, only one in two adults with osteoporosis aged 65 and older received a prescription for an anti-osteoporosis drug. $756 million (77 %) was attributable to brand name drugs which accounted for 2,459,931 claims (22 %). Generic dispensing rate varied from 57-86 % (mean 77 ± 6) across the different states in the USA. States that mandate substitution with generic equivalents had a higher generic dispensing rate compared to the states that permit generic substitution (92 vs. 90 %; p < 0.05). After adjusting for claim counts, we found that if the states that permit substitution with generic equivalents showed the same generic dispensing rate of 92 % as the states that mandate such substitution, there is a potential for savings of $7.5 million, approximately 9 % of the total expenditure in these states on oral bisphosphonates alone. Thirty-eight percent of the total prescriptions from orthopedic surgeons were for Forteo® or Prolia® compared to 12.5 % from specialists.
These findings highlight the need for ongoing training for physicians who engage in the care of patients with osteoporosis to manage the disease in a cost-effective manner.
预防和治疗骨质疏松症以预防骨折有着强大的推动力。2013年在抗骨质疏松药物上花费了9.9亿美元。随着我们将重点转向骨折的一级预防,鼓励医疗服务提供者为患者找到最具成本效益的抗骨质疏松治疗方法。
骨质疏松症是一个全球性主要问题,骨质疏松性骨折给医疗资源带来了潜在的可避免负担。我们使用2013年医疗保险D部分的数据研究了抗骨质疏松治疗的使用情况和成本。
利用微软Excel和SPSS生成了关于感兴趣的抗骨质疏松药物的描述性数据。
2013年,医疗保险及其受益人在抗骨质疏松治疗上总共花费了约9.9亿美元。尽管有这笔费用,但65岁及以上的骨质疏松症成年患者中只有二分之一获得了抗骨质疏松药物的处方。7.56亿美元(77%)归因于品牌药,品牌药占2459931份理赔申请(22%)。美国不同州的通用药物配给率从57%至86%不等(平均77±6)。强制使用通用等效药物替代的州与允许通用替代的州相比,通用药物配给率更高(92%对90%;p<0.05)。在调整理赔申请数量后,我们发现,如果允许使用通用等效药物替代的州显示出与强制进行此类替代的州相同的92%的通用药物配给率,仅在这些州的口服双膦酸盐类药物总支出方面就有可能节省750万美元,约占总支出的9%。骨科医生开出的总处方中有38%是福善美或普罗力,而专科医生开出的这一比例为12.5%。
这些发现凸显了对从事骨质疏松症患者护理工作的医生进行持续培训的必要性,以便以具有成本效益的方式管理该疾病。